DPYSL5 and lung cancer: Regarding diseases associated with anti-CV2/CRMP5 antibodies, there is a high risk of tumor coexistence (>80%), frequently including thymoma, a generally benign anterior mediastinal tumor, and SCLC, an aggressive form of lung cancer [44].